{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:44:11Z","timestamp":1792107851258,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.radonc.2024.110439","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T01:53:22Z","timestamp":1721354002000},"page":"110439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-7575","authenticated-orcid":false,"given":"Gustavo A.","family":"Viani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-3557","authenticated-orcid":false,"given":"Andre G.","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Arcidiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Carolina Hamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Anselmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Y.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110439_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.radonc.2024.110439_b0010","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3892\/mco.2014.252","article-title":"Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer","volume":"2","author":"Ishida","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110439_b0020","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.2011.39.5269","article-title":"Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans","volume":"30","author":"Wang","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JTO.0b013e3181c5920c","article-title":"Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey","volume":"5","author":"Morgensztern","year":"2010","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.radonc.2024.110439_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/annonc\/mdu268","article-title":"A review of the management of elderly patients with non-small-cell lung cancer","volume":"26","author":"Blanco","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.lungcan.2013.06.011","article-title":"Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer","volume":"82","author":"Sigel","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110439_b0050","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2021.05.003","article-title":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study","volume":"16","author":"Jazieh","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2004.04.013","article-title":"Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer","volume":"60","author":"Rengan","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0065","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.21007","article-title":"Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma","volume":"103","author":"Rosenzweig","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110439_b0070","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2006.04.034","article-title":"Final results of a Phase I\/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy","volume":"66","author":"Belderbos","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0085","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0090","first-page":"e20210390","article-title":"Stereotactic body radiotherapy versus surgery for early-stage non-small cell lung cancer: an updated meta-analysis involving 29,511 patients included in comparative studies","volume":"48","author":"Viani","year":"2022","journal-title":"Jornal Brasileiro de Pneumologia"},{"key":"10.1016\/j.radonc.2024.110439_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107281","article-title":"Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines","volume":"182","author":"Yan","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110439_b0100","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2012.11.011","article-title":"Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study","volume":"85","author":"Feddock","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0105","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study","volume":"12","author":"Higgins","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2018.03.024","article-title":"Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial","volume":"127","author":"Doyen","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0115","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110439_b0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE Reporting Guidelines for Meta-analyses of Observational Studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surgery"},{"key":"10.1016\/j.radonc.2024.110439_b0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijrobp.2022.10.025","article-title":"STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial","volume":"115","author":"Arcidiacono","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/COC.0000000000000892","article-title":"Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study","volume":"45","author":"Kubicek","year":"2022","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0140","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.radonc.2024.110439_b0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jrr\/rrz044","article-title":"Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3\u20134N0M0 (UICC 8th edition): outcomes and patterns of failure","volume":"60","author":"Narita","year":"2019","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110439_b0150","first-page":"59","article-title":"Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities","volume":"5","author":"Karam","year":"2014","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.radonc.2024.110439_b0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jrr\/rrw023","article-title":"Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer","volume":"57","author":"Eriguchi","year":"2016","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110439_b0160","first-page":"08010","article-title":"Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors","volume":"S0360\u20133016","author":"Friedes","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0165","doi-asserted-by":"crossref","unstructured":"Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial [published correction appears in Lancet. 2023;402(10405):850]. Lancet. 2023;402(10405):871-881. doi:10.1016\/S0140-6736(23)01384-3.","DOI":"10.1016\/S0140-6736(23)01384-3"},{"key":"10.1016\/j.radonc.2024.110439_b0170","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0175","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0180","doi-asserted-by":"crossref","unstructured":"Drouet F, Lagrange JL. Dose de tol\u00e9rance \u00e0 l'irradiation des tissus sains: la moelle osseuse [Normal tissue tolerance to external beam radiation therapy: bone marrow]. Cancer Radiother. 2010 Jul;14(4-5):392-404. French. doi: 10.1016\/j.canrad.2010.04.006.","DOI":"10.1016\/j.canrad.2010.04.006"},{"key":"10.1016\/j.radonc.2024.110439_b0185","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.radonc.2014.02.002","article-title":"Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance","volume":"110","author":"Kestin","year":"2014","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0195","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4143\/crt.2013.168","article-title":"Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors","volume":"46","author":"Park","year":"2014","journal-title":"Cancer Research and Treatment"},{"key":"10.1016\/j.radonc.2024.110439_b0200","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.ijrobp.2011.04.034","article-title":"Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis","volume":"81","author":"Zhang","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110439_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109664","article-title":"Local control correlates with overall survival in radiotherapy for early-stage non-small cell lung cancer: A systematic review","volume":"183","author":"Sanuki","year":"2023","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0210","author":"Heinzerling","year":"2023","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0215","author":"Heinzerling","year":"2023","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110439_b0225","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement","volume":"146","author":"Guckenberger","year":"2020","journal-title":"Radiotherapy and Oncology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024007096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024007096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T19:18:48Z","timestamp":1732303128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024007096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"alternative-id":["S0167814024007096"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110439","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110439"}}